Acalabrutinib meets primary efficacy endpoint in head-to-head trial against ibrutinib in chronic lymphocytic leukemia (CLL) ELEVATE-RR Phase 3 trial

Results from ELEVATE-RR (n=533) showed acalabrutinib (100mg, orally, twice daily) was non-inferior for progression-free survival in adults with previously treated CLL compared to ibrutinib (420mg orally once daily). Both treatments are licensed for CLL in the UK.

Source:

Biospace Inc.